Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gardasil-9 Booster for Recurrent Respiratory Papillomatosis
NCT07339163Phase 2Not yet recruiting
- Sponsor
- The Ohio State University
- Start
- Dec 2026
- Primary completion
- Apr 2028
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of recombinant human papillomavirus 9-valent vaccine in recurrent respiratory papillomatosis (RRP), sponsored by The Ohio State University. Primary endpoints: Intersurgical Interval at 5 years and Safety and Adverse Events at 5 years. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
recurrent respiratory papillomatosis (RRP)
Beyond the preview
Go deeper on NCT07339163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07339163.